Please use this identifier to cite or link to this item:
|Title:||Molecular mechanisms of tumor resistance to PI3K-mTOR-targeted therapy|
|Citation:||Tan, J., Yu, Q. (2013). Molecular mechanisms of tumor resistance to PI3K-mTOR-targeted therapy. Chinese Journal of Cancer 32 (7) : 376-379. ScholarBank@NUS Repository. https://doi.org/10.5732/cjc.012.10287|
|Abstract:||Deregulation of the phosphatidylinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) signaling pathway occurs frequently in a wide range of human cancers and is a major driving force in tumorigenesis. Thus, small molecules targeting this pathway are under active development as anticancer therapeutics. Although small-molecule inhibitors of the PI3K-mTOR pathway have shown promising clinical efficacy against human cancers, the emergence of drug resistance may limit their success in the clinic. To date, several resistance mechanisms, including both PI3K-dependent and -independent mechanisms, have been described. Here, we summarize the current understanding of resistance mechanisms to PI3K-mTOR inhibitors and discuss potential strategies for overcoming resistance for potential clinical application. © Chinese Journal of Cancer.|
|Source Title:||Chinese Journal of Cancer|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Aug 16, 2018
WEB OF SCIENCETM
checked on Jul 24, 2018
checked on Aug 17, 2018
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.